Recurrent Squamous Cell Carcinoma of the Larynx Completed Phase 1 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0028811 (Recurrent Squamous Cell Carcinoma of the Larynx)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00004074Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuTreatment